



December 10, 2018

**Conduct a study to identify and measure specific biomarkers in ALS
- we will strive to deliver a beneficial therapy option to patients -**

Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President & Representative Director, CEO: Masayuki Mitsuka), announced today that Mitsubishi Tanabe Pharma America, Inc. (MTPA), MTPC's US subsidiary, announced it will conduct a study to identify specific biomarkers about the disease progress in people with amyotrophic lateral sclerosis (ALS).

The outline of this study is as follows:

- Goal: Evaluate biomarkers in order to gain insights into how the disease progresses and potentially optimize treatment effect of edaravone in ALS patients.
- Participants: approximately 200 adults with ALS in 30 sites across the U.S.
- Evaluate period: 24 weeks
- Methods: All participants will be newly prescribed commercial RADICAVA and once enrolled in this study, biomarker and clinical assessments will be obtained prior to initiating RADICAVA. The study will evaluate biomarkers, as Oxidative stress, Inflammation, Neuronal injury and death, Muscle injury etc.

MTPA has announced the study at 29th Annual International Symposium on ALS/MND December 7-9, 2018, in Glasgow, Scotland.

MTPC group will gain insights into how the disease progresses and optimize treatment effect of edaravone, and will strive to deliver a beneficial therapy option to ALS patients.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110